Suzetrigine vs Norco-postoperative Mohs Pain

Part of paid clinical trials in Dallas, Texas.

Sponsor
Baylor Research Institute
Study ID
NCT07575230
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

  • Cutaneous Tumors
  • Mohs Micrographic Surgery

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • Norco 5Mg-325Mg Tablet — DRUG
    Standard of care drug
  • Suzetrigine — DRUG
    Control Drug

Study Details

To compare suzetrigine versus hydrocodone/acetaminophen for postoperative pain control following dermatologic surgery.

Key Dates

Start date
Nov 3, 2025
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Standard of Care
    Participants will receive the standard of care drug Norco (a medicine that combines hydrocodone and acetaminophen).
  • Active Comparator: Control
    Participants will receive the control drug, Suzetrigine.

Primary Outcome Measure

Change in need for opioid medication for pain management after Mohs micrographic surgery [ Time Frame: 48hours post surgery ]

Locations (1)

FacilityCityStateZIPSite coordinators
Baylor University Medical CenterDallasTexas75246-

Find similar trials in Dallas, TX

By research site
Baylor University Medical Center· Dallas, TX

Related Studies